COVAG - Covid-19 Antigen Study - the Diagnostic Efficacy of SARS-CoV-2 Rapid Detection Tests (COVAG)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05074017|
Recruitment Status : Completed
First Posted : October 12, 2021
Last Update Posted : October 20, 2021
The aim of the COVAG study (Covid-19 Antigen study) is to assess the diagnostic efficacy of two of the most used rapid antigen tests (Roche & Abbott).
The study will be performed at the Corona Test Center Stuttgart Cannstatter Wasen. Approximately 2000 patients will be enrolled after having signed the Informed Consent Form (ICF). Each patient will receive 3 nasopharyngeal swabs. Two for the rapid antigen tests from Roche and Abbott and one for the RT-PCR. Furthermore an anamnesis, short clinical examination and blood draw is done. The blood is examined for SARS-CoV-2 antibodies and basic laboratory tests to be communicated to participants.
|Condition or disease||Intervention/treatment|
|COVID-19 SARS-CoV2 Infection SARS (Disease)||Device: 3 nasopharyngeal swab|
|Study Type :||Observational|
|Actual Enrollment :||2222 participants|
|Official Title:||COVAG Study - Covid-19 Antigen Study|
|Actual Study Start Date :||February 1, 2021|
|Actual Primary Completion Date :||March 31, 2021|
|Actual Study Completion Date :||March 31, 2021|
- Device: 3 nasopharyngeal swab
3 nasopharyngeal swabs to conduct 2 rapid antigen tests for SARS-CoV-2 and a RT-PCR
- Sensitivity of the rapid antigen tests [ Time Frame: 31.03.2021 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05074017
|SYNLAB MVZ Leinfelden-Echterdingen GmbH|
|Corona Testzentrum Cannstatter Wasen|
|Study Director:||Winfried März, Prof. Dr. med||Synlab Holding Deutschland GmbH|